Chemistry:Ibcasertib
From HandWiki
Ibcasertib is an investigational new drug that is being evaluated to treat small-cell lung cancer.[1] Ibcasertib inhibits several angiogenesis-related kinases, including VEGFR1, VEGFR2, VEGFR3, PDGFRα, and c-Kit, as well as the mitosis-related kinase Aurora B and the chronic inflammation-related kinase CSF-1R.[2]
References
- ↑ "Ibcasertib - Chipscreen Biosciences". AdisInsight. Springer Nature Switzerland AG. https://adisinsight.springer.com/drugs/800040530.
- ↑ "CS2164, a novel multi-target inhibitor against tumor angiogenesis, mitosis and chronic inflammation with anti-tumor potency". Cancer Science 108 (3): 469–477. March 2017. doi:10.1111/cas.13141. PMID 28004478.
 |  |
